# Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

> **NCT04711902** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** AIN457
- **OTHER:** Secukinumab Placebo

## Key facts

- **NCT ID:** NCT04711902
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-24
- **Primary completion:** 2022-06-02
- **Final completion:** 2023-03-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711902, "Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04711902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*